 |
|
|
| |
98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Jia-Horng Kao,1 Sang-Hoon Ahn,2 Rong-Nan Chien,3 Sook-Hyang Jeong,4 Cheng-Yuan Peng,5 Young-Suk Lim,6 Jenny C. Yang,7 Hongmei Mo,7 Ling-Ling Han,7 Diana M. Brainard,7 Steven J. Knox,7 John G. McHutchison,7 Youn-Jae Lee,8 Ting-Tsung Chang,9 Seung-Woon Paik,10 Chi-Jen Chu,11 Wan-Long Chuang,12 Kwang-Hyub Han2
1National Taiwan University Hospital, Taipei, Taiwan; 2Severance Hospital, Yonsei University Health System, Seoul, Korea; 3Chang Gung Memorial Hospital-Keelung, Keelung, Taiwan; 4Seoul National University Bundang Hospital, Seoul, Korea; 5China Medical University, Taichung, Taiwan; 6Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; 7Gilead Sciences, Inc., Foster City, California, USA; 8Inje University, Pusan Paik Hospital, Busan, Korea; 9National Cheng Kung University Hospital, Tainan, Taiwan; 10Samsung Medical Center, Seoul, Korea; 11Taipei Veterans General Hospital, Taipei, Taiwan; 12Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
|
| |
|
|
|
|
|
